Abstract
Psychotic symptoms in Parkinson’s disease are relatively common and include hallucinations, illusions, and delusions. Psychosis is a major cause of disability and is one of the most distressing symptoms for both patients and caregivers. The management of psychosis is often complex and challenging and involves determining the degree and severity of psychotic symptoms and whether intervention is required. In this review, the authors describe the phenomenology and risk factors of Parkinson’s disease psychosis (PDP) and current evidence-based treatment options. In randomized, double-blind, placebo-controlled trials, pimavanserin was found to be effective and well-tolerated in PDP but its onset of benefit takes 4–6 weeks. Present reviews of evidence-based medicine suggest that low doses of clozapine can provide benefit without worsening PD motor symptoms. While quetiapine is frequently used, its efficacy is not supported by randomized, double-blind, placebo-controlled trials. Clozapine and pimavanserin have proven efficacy in the treatment of PDP, without impairing motor function. Therefore, these agents should be considered first-line treatment of PDP at this time. Although quetiapine did not show efficacy in PDP, many PD experts use it as it does not worsen motor function and lacks the blood monitoring requirement of clozapine.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.